Bradley Lorimier, James Niedel | GenomeWeb

Bradley Lorimier, James Niedel

Premium

Psychiatric Genomics of Gaithersburg, Md., which uses gene expression analysis of brain and other human tissues to develop medications for mental illness, has appointed Bradley Lorimier to its board of directors and as a business development consultant. Lorimer currently consults within the pharmaceutical industry and serves on the boards of four companies. Lorimer retired from his position as senior vice president of business development for Human Genome Sciences in 1997.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.